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Kowalski et al 2019, Nagasaki et al 2015). In these settings, the capacity to link genetic variants
with phenotypic traits, pathological conditions, and/or positive or adverse reactions to therapies and




prevent   the  disease  or  mitigate  its   severity.  Accordingly,     numerous  countries   and   institutions







for  a  new revolution   in  medical  science  and human genetics,   the  need  to  handle,  analyze  and
interpret   large  collections  of   “big”  genomic  data   is   posing  major   challenges   to  genomics  and
bioinformatics which at present remain unresolved (Alyass et al, Klein et al 2017, 2015, Horowitz
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In this paper, we present VINYL, a novel fully automated workflow for the prioritization of genetic
variants in clinical studies. By building on guidelines and recommendations derived from clinical














our   tool   to   a   cohort   of   38   patients   with   a   diagnosis   of   dilated   cardiomyopathy   (DCM),
arrhythmogenic right ventricular cardiomyopathy (ARVC) or hypertrophic cardiomyopathy (HCM)
who were previously subjected to genotyping by targeted resequencing of a panel of 115 genes





dataset.   All   in   all,   we   believe   that   by   providing   a   rapid   and   systematic   approach   for   the
prioritization of genetic variants, VINYL can greatly facilitate the identification of pathogenic or
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(Wang   et   al,   2010),   using   a   collection   of   “standard”   resources  maintained   by   the   Annovar
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Pathogenic   or   Likely   Pathogenic   in   publicly   available   resources   of   clinically   relevant
variants.  The   score   is   decreased   for   variants   that   are   reported   as   “Benign”  or   “Likely
Benign”. Users can provide a description of the disease and its symptoms using   a simple
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● Regulatory element (Reg):  the score is  incremented if  the variant  is part  of a genomic









● Splicing   variants   (Sp):  the   score   is   incremented   if   the   variant   is   reported   to   have   a
deleterious effect on a splice site according to the  dbscsnv11 (Jian et al, 2014) database











search  on  the  parameter   space.    Score  distributions  are  computed   for  a  population  of  affected
individuals  (A) and a population of healthy controls (C).    The optimal  scoring system and  the
corresponding threshold for the identification of potentially pathogenic variants are established by
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identified   in   the  A and C populations  are   recorded.    A Fisher’s  Exact   test   is  used  to   test   the
significance of the over­representation of likely pathogenic variants in A with respect to C. Finally,
the scoring system (and the corresponding threshold value) that maximizes the difference between
the number of potentially pathogenic variants identified in  the  population of  affected individuals
with   respect   to   the   control  population,  and   that,   at   the   same   time,  minimizes   the   number   of











genetic   algorithms   used   for   the   optimization   of   the  VINYL  pathogenicity   score   can   robustly
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Cohorts   of   different   size,   formed  by  25,   50   and  100   individuals   respectively  were   simulated,
including a variable number of polymorphic positions: 1000, 5000 and 10000,  to simulate different
sequencing strategies.     Disease­associated variants have been simulated by randomly selecting a
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VINYL provides  a   fully  automated  system for   the  prioritization  of  pathogenic  variants,  which





files.  Variants  annotation   is  performed by  the  Annovar  software  (Wang et  al,  2010),  which   is
available in VINYL along with an extensive collection of resources for the annotation of genetic
variants   (see   Table   S1).   Additional   information,   which   is   used   for   the   computation   of   the




simple  configuration   files   in  plain   text   format   (see  Material   and  Methods,   and  Supplementary
Materials) .
The  main  output   consists   of   a   tabular   file,   where   variants   are   ranked   according   to   their
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limited number of genes to  WES).  Finally,   to  investigate  the ability of  the tools considered  to
correctly prioritize disease­associated variants of different types, a matched number of variants with
different predicted functional effects were simulated (see Materials and Methods).  
As  outlined   in  Table  1  and  Figure  2,  we observe   that,  while  achieving a   remarkable   level  of
accuracy,  with   a   false   positive   rate   that   is   consistently   below   1%,  VINYL   demonstrates   an













variant  prioritization system, we reasoned  that  the choice of  the correct background population
could have a major impact on the accuracy or our tool, thus limiting the applicability of VINYL to
only cases when a control population with a similar genetic background is available.   To test this
hypothesis   we   repeated   our   analyses   of   simulated   data   by   using   3   distantly   related   human
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scores   related   to   allele   frequency   and   over­representation   of   alleles   in   the   population   were
systematically reduced in these settings, suggesting that reduction in sensitivity could be related to
the   presence   of   mildly   deleterious   polymorphisms   showing   a   population   biased   frequency














composed   of   38   Italian   patients   affected   by   different   types   of   cardiomyopathies,  which  were
previously   subjected   to  genotyping  by   targeted   resequencing  of   a  panel  of  115  genes.  Expert
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displayed a  pathogenicity  score  higher   than   the  pathogenicity  score  cut­off  value   identified  by
VINYL,  suggesting   that  our  method achieves  high   levels  of   specificity   (Figure  3B).    Notably,

























Mann  Whitney  Wilcoxon   test   is   used   to   identify   genes   showing   a   significant   increase   in
pathogenicity   score.  Only   genes   showing   a   significant   p­value   are   reported   in   the   output.  To
facilitate a rapid comparison, score distributions are represented in the form of   boxplots. Dotted
lines are used to indicate the “pathogenicity” cut­off value. 
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Discussion
The   application   of   genome   sequencing   technologies   to   clinical   practice   is   promising   a  major
breakthrough in clinical sciences. However,   the systematic  integration of genomics into clinical
applications poses several challenges, most of which remain unresolved at present.  Among these,




manual   curation   by   an   expert   clinician   is   normally   required.   Moreover,   since   different
operators/researchers tend to use slightly different methods, criteria, and resources for the functional














and resources  by  the  user.    By building  on  the popular  Galaxy workflow manager,  VINYL is
accessible   through a  simple yet  powerful  web  interface,  which enables  collaborative work and
facilitates the reproducibility of bioinformatics analyses. Encrypted data volumes are used to ensure
high levels of data protection.  Extensive simulations and analysis of a real dataset, suggest that the
approach   adopted   by   VINYL   achieves   high   levels   of   sensitivity   and   specificity   in   different
experimental conditions, and more important that our method outperforms currently available state
of   the  art   tools   in  all   the  conditions  herein   tested.  Although  the   requirement  of    a  genetically
homogeneous     “control”   population,   and   the   need   for   a   relatively   large   cohort   of   affected
individuals, limit the applicability of VINYL in cases where only a very limited number of samples
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is available (see for example analyses of TRIOs or of single patients), we believe that the approach






























.CC-BY-NC-ND 4.0 International licenseauthor/funder. It is made available under a











































.CC-BY-NC-ND 4.0 International licenseauthor/funder. It is made available under a











































.CC-BY-NC-ND 4.0 International licenseauthor/funder. It is made available under a



















       Zhang L, Zhang J, Yang et al PriVar: a toolkit for prioritizing SNVs and indels from next­
generation   sequencing   data.   Bioinformatics.   2013   Jan   1;29(1):124­5.   doi:
10.1093/bioinformatics/bt
.CC-BY-NC-ND 4.0 International licenseauthor/funder. It is made available under a
The copyright holder for this preprint (which was not peer-reviewed) is the. https://doi.org/10.1101/2020.01.23.917229doi: bioRxiv preprint 
Table Legends
Table1: Sensitivity and specificity on simulated data.  Levels of sensitivity and specificity of VINYL, Privar and








Sens Spec Sens Spec Sens Spec
25
VINYL 73,01 99,66 78,89 99,29 89,95 99,69
Privar 54,97 93,44 59,79 91,64 61,58 93,57
KGGSeq 62,29 95,55 64,03 96,77 59,93 96,96
50
VINYL 78,64 99,52 86,14 100,36 94,35 99,72
Privar 56,66 94,01 58,60 90,04 59,95 90,79
KGGSeq 63,92 95,05 66,37 96,60 65,90 94,56
100
VINYL 82,69 99,89 90,47 99,04 96,27 99,82
Privar 55,80 89,87 58,06 91,34 59,63 91,77




Sens Spec Sens Spec Sens Spec
25
VINYL 76,95 99,32 82,90 99,33 91,50 99,96
Privar 58,27 92,47 61,67 91,70 63,30 92,99
KGGSeq 63,21 95,55 64,52 95,93 60,60 96,13
50
VINYL 80,75 99,41 87,12 99,54 96,03 99,26
Privar 56,84 93,54 58,84 89,80 62,40 90,36
KGGSeq 63,68 94,42 69,78 95,94 67,35 94,10
100
VINYL 84,53 99,25 93,83 99,17 99,86 99,63
Privar 58,47 89,89 62,42 90,59 60,78 91,06




Sens Spec Sens Spec Sens Spec
25
VINYL 78,41 99,48 84,01 99,40 92,23 99,66
Privar 62,70 92,60 64,17 91,87 64,53 93,11
KGGSeq 69,85 95,75 67,57 96,08 61,25 96,30
50
VINYL 82,95 99,55 88,44 99,63 98,29 99,45
Privar 59,84 93,69 62,06 89,87 65,02 90,52
KGGSeq 65,59 94,59 73,40 96,07 68,64 94,27
100
VINYL 88,38 99,42 97,32 99,39 99,29 99,85
Privar 61,53 89,91 65,48 90,77 64,08 91,12
KGGSeq 68,82 95,49 70,21 96,28 72,02 96,51
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Figure Legends






identified as   the  threshold  that  maximizes   the number of potentially  pathogenic variants   in   the cohort  of  affected
individuals, while at the same time minimizing the number of potentially pathogenic variants in the control population.
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Figure2: Boxplot of AUC values.  Distribution of ROC Area Under the Curve (AUC) values for KGGseq, VINYL and Privar in the detection of simulated pathogenic variants.
Distributions of AUC are represented in the form of a boxplot. Panel A, B and C indicate simulations with odd Risk Ratio values of 3, 10 and 20 respectively.
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Figure 3: Comparison of VINYL with other start of the art methods for variant prioritization. A) proportion of
variants in the population of affected individuals prioritized by each tool. B) Proportion of variants prioritized by each
tool   in   the  population  of   controls.  These   represent   likely   false  positive   calls.  C)  Proportion  of  manually   curated
pathogenic   variants   according   to   Forleo   et   al   2017   recovered   by   each   tool.   Orange=VINYL,   Blue=Privar,
Green=KGGseq.
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